To date, age-dependent frequencies of estrogen receptor-positive (ER+) and negative (ER−) breast cancer types have been identified and tests that detect predictive mutations (e.g., BRCA1 [103]) have been developed and implemented in clinical practice. This evidence concerns the gene ESR1 and breast carcinoma.